Estimating the Daily Milligrams of Morphine Equivalent of Illicit Fentanyl Use in Los Angeles: Clinical and Epidemiological Implications

Morgan Godvin, BA[1*], Joseph R. Friedman, MD, PhD, MPH[2*], Caitlin A. Molina, BS, BA[1], Adam J. Koncsol, MPA[1], Ruby Romero, BA[1], David N. Juurlink, MD, PhD, FRCPC[3], Chelsea L. Shover, PhD[1**]

1. Division of General Internal Medicine and Health Services Research, University of California, Los Angeles, United States
2. Department of Psychiatry, University of California, San Diego, United States
3. Departments of Medicine, Pediatrics, and Health Policy, Management and Evaluation, University of Toronto, Canada

*Co-first authors; authors contributed equally to this work.
**Correspondence to Chelsea L. Shover, PhD, clshover@mednet.ucla.edu

Abstract

Introduction

The market shift from heroin to illicitly-manufactured-fentanyl in North America led to surging rates of opioid overdose and mortality. However, limited detailed information exists about the dose of fentanyl regularly consumed by individuals with opioid use disorder. We examined purity of fentanyl samples and estimate the typical daily oral milligrams of morphine equivalent (MME) consumed.

Methods

Leveraging community-based drug checking data from Los Angeles, we ascertained the purity of 384 samples of fentanyl collected between September 2023 and July 2025 using liquid chromatography mass spectrometry. We assessed typical consumption quantity and routes of administration among 31 respondents who reported regularly using fentanyl. We drew bioavailability estimates and approximate MME conversion factors from literature. To estimate daily MME consumed, and incorporate uncertainty from all parameters, we used a bootstrapping model with 10,000 draws.

Results

Among participants, the median daily consumption of fentanyl was 1.0 grams (1000 milligrams). Illicit fentanyl products had a median fentanyl purity of 9.4%., and the median estimated bioavailability based on routes of administration was 72.3%. Using a median IV fentanyl to PO morphine conversion factor of 1:182, the median estimated daily consumption in our sample was 10,933 MME (IQR 25,272 MME).

Conclusions

We estimate that individuals consuming illicit fentanyl in Los Angeles use quantities of opioids that are several orders of magnitude higher than clinical guidelines or typical methadone doses. This undoubtedly contributes to high overdose mortality rates and reflects a high tolerance among

individuals with OUD. It also likely undermines the success of medications for OUD at conventional doses.

Introduction

Since the early 2010s, the North American overdose crisis has been driven primarily by illicit fentanyl and its analogues.[1,2] As a synthetic opioid easily produced in large quantities, illicit fentanyl has become a drug of choice for many consumers because it is inexpensive and readily available.[3] Fentanyl is far more potent than opioids derived from the opium poppy such as heroin and oxycodone, with a milligram of morphine equivalence (MME) conversion factor between intravenous (IV) fentanyl and oral (PO) morphine estimated to range between 1:66 and 1:300[4–6]. It is generally understood that fentanyl's high potency makes it easy for individuals to inadvertently consume more than intended, leading to greatly elevated overdose death rates.[1,7] However, detailed information about the actual doses of illicit fentanyl consumed in real-world settings by individuals with opioid use disorder (OUD) is extremely limited. For substance use disorders involving legal substances like alcohol and tobacco, exposure quantification is part of the standard approach to treatment, with metrics such as drinks per day and pack-years codified in clinical guidelines. In the illicit market, however, exposure quantification is more difficult, given lack of quality control and the shifting composition of illicit drug products.[8] Patients are often unaware of the actual drugs and amounts in their supply, and reliable dosing guidance can be difficult to ascertain. Consequently, there are important potential clinical and epidemiological benefits of quantifying illicit fentanyl consumption among individuals with OUD. These include improved withdrawal management[9], improvements in dosing guidance with medications for opioid use disorder (MOUD)[10], and better characterization of the risk environment for this population[11].

Leveraging advancements in community-based drug checking approaches[12–15] and analytical technologies[16,17], we quantified the purity of illicit fentanyl samples in Los Angeles and combined this

with self-reported consumption quantities to estimate the daily MME consumed by participants in a drug checking program who reported recent fentanyl use.

Methods

We analyzed 384 drug samples collected between September 2023 and July 2025 at *Drug Checking Los Angeles*, a community-based drug checking program with multiple sites across Los Angeles County. These samples were drawn from a larger pool of n=1,983 collected during this period; the subset of 384 represents those for which a) quantitative fentanyl results were available and b) samples were expected by participants to contain fentanyl. Drug samples were provided anonymously and voluntarily by drug checking participants. For each sample, a few milligrams of drug product were transferred into a vial containing 0.5 mL acetonitrile. Samples were analyzed at the National Institute of Standards and Technology (NIST) using liquid chromatography mass spectrometry (LC-MS) [see previously published methods[15–18]]. Similar to previous analyses, fentanyl purity was defined as the combined percentage by weight of each sample represented by either fentanyl or fluorofentanyl; these compounds are of comparable potency and impart comparable biologic effects[19].

Drug checking participants were invited to answer a brief, confidential survey about their recent drug use. Among 31 unique respondents who reported using fentanyl in the past 30 days, we assessed consumption (grams per day), and routes of administration (see supplement for more details). For each route of administration, we drew bioavailability estimates from a literature review of experimental data (see supplement). IV fentanyl to PO morphine MME conversion factors were also drawn from literature review (see supplement) and ranged from 1:66 to 1:300, with a median of 181.9.

We estimated daily MME consumed by drug checking participants in Los Angeles according to the following formula:

$$Estimated\ Consumption\ (in\ MME) = Mass\ consumed\ * Purity * Bioavailability * MME\ Equivalence$$

Equation 1. Calculation of estimated daily milligrams of oral morphine equivalent (MME) used among regular consumers of fentanyl, who visited drug checking services in Los Angeles

83 In this equation, $Mass\ Consumed$ is the estimated quantity of illicit fentanyl product used per day in
84 milligrams, *Purity* is the proportion of active compound in product expected to be fentanyl,
85 *Bioavailability* is the route of administration-specific proportion of total drug used that reaches the
86 systemic circulation, $MME\ Equivalence$ is a metric used to convert doses of different opioids into an
87 approximately equivalent dose of oral morphine to allow for consistent comparisons of potency and
88 risk, which are based on the estimated ratio of physiological potency between IV fentanyl and oral
89 morphine[4–6].

90 Each of the elements in this equation is associated with a degree of uncertainty. To estimate
91 MME consumed, incorporating uncertainty and individual variation in each parameter, we used a
92 bootstrapping approach. This entailed creating 10,000 draws of each parameter and calculating MME
93 over 10,000 iterations, yielding a distribution of estimated MME values. As with previous analyses using
94 drug checking purity data, and given the skewed distributions of several parameters, we used median
95 values to describe 'typical' values and the 'average' individual[14].

96 This project received approval by the UCLA IRB (IRB-22-0760). All analyses were conducted in R
97 version 4.4.1.

98 **Results**

99 Among the 31 participants reporting past 30-day fentanyl use and consumption quantity, the median
100 daily consumption of product sold as fentanyl consumed was 1.0 grams, with a range from 0.033 grams
101 to 4.0 grams daily (Figure 1). Products sold as fentanyl had a median fentanyl purity (combined
102 concentration of fentanyl and fluorofentanyl, as applicable) of 9.4%, with a range from 0.1% to 64.9%.
103 Almost all participants (n=30; 97%) reported smoking/vaporizing fentanyl. Many (n=12; 39%) also
104 reported intravenous injection, and 7 (23%) reported nasal insufflation. One participant reported
105 exclusively oral ingestion, and one reported both oral ingestion and smoking. Assuming equal
106 consumption via each method when participants reported multiple routes of administration, and

107 accounting for uncertainty in bioavailability associated with each method (see supplemental methods),
108 the median estimated bioavailability was 72.3%. The MME conversion factor, drawn from literature
109 values, was represented by a uniform distribution, with a range of 66 to 300, and a median of 181.9.
110 Incorporating each of the above factors, the median participant consumed a daily estimated
111 MME of 10,933.0 MME (Figure 1). Estimated MME had a skewed distribution, reflecting skewed
112 distributions in several underlying parameters. The first quartile was 2,895.8 MME, and the third
113 quartile was 28,167.9 MME, yielding an interquartile range of 25,272.1 MME.

114 Discussion

115 Using drug samples from the real-world illicit drug supply in the Los Angeles area, we found that
116 one gram of a product understood to be "fentanyl" in fact contained a range of <1 mg to 697 mg of
117 fentanyl. Combining this with survey data from people who report recent, regular fentanyl use, we
118 estimate that a typical consumer of illicit fentanyl uses the equivalent of approximately 11,000
119 milligrams of morphine daily, an extraordinary amount when considered in light of treatment guidelines
120 that discourage doses in excess of 90 milligrams daily for the treatment of chronic pain.[20]
121 It is generally recognized that as a result of tolerance, opioids have no set upper dose threshold,
122 and that usage quantities can escalate rapidly among individuals with OUD who have ample access to
123 opioids. It has also been previously described that the illicit market shift from heroin to illicit fentanyl
124 drastically increased the potency of illicit opioid products, a key factor in skyrocketing rates of overdose
125 and mortality[1,11]. To our knowledge, this analysis represents the first effort to quantify these
126 phenomena in estimated MME consumed per day among individuals consuming illicit opioids in the
127 fentanyl era.
128 The advent of community-based drug checking techniques provides a powerful opportunity to
129 open the 'black box' of illicit drug products, and quantify drug contents with accuracy and precision[12,21].
130 We find that the typical product sold in Los Angeles as fentanyl, and expected to be illicit fentanyl, is

131 nearly 10% pure. One gram of this product, sold for approximately $100 USD in Los Angeles, would
132 contain 100 mg of active fentanyl, roughly 100-fold higher than a typical daily amount used for IV
133 analgesia in an opioid-naïve adult. However, purity of illicit fentanyl samples in Los Angeles is also highly
134 variable, ranging from 0.1% to 64.9% among quantified samples. A gram of illicit fentanyl could
135 therefore contain from about 180 MME to about 116,000 MME. Assumptions about bioavailability and
136 MME conversion factors influence the overall estimated dosage. However, under all plausible scenarios,
137 individuals consuming illicit fentanyl in Los Angeles on average appear to be consuming MME ranges
138 many orders of magnitude above clinical dosing regimens.

139 This high—and highly variable—potency illustrates the impact of illicit fentanyl on the risk
140 environment for people with OUD. The extraordinarily elevated overdose risk in the fentanyl era can be
141 understood, in part, as a logical consequence of extreme variations in purity, wherein a gram of street
142 product can vary wildly in its overall opioid content.

143 Our findings illustrate how insights gleaned from drug checking data can have potential
144 implications for clinical practice—in particular, withdrawal management and stabilization of patients
145 initiating MOUD. High average MME content of illicit fentanyl samples is reflected in the extremely
146 elevated tolerance noted among people using illicit opioids. Many individuals report difficultly returning
147 to heroin use after initiating illicit fentanyl use [2=7]. Similarly, methadone dosing requirements have also
148 increased sharply in the fentanyl era[23].

149 Methadone and buprenorphine are the best evidence-based treatments for OUD, and their use
150 is associated with marked reductions in mortality rates[24]. Nevertheless, a large and growing body of
151 evidence suggests that MOUD initiation has become more difficult in the fentanyl era, with uptake of
152 MOUD and engagement in treatment among people with OUD remaining low in the United States[25]. Our
153 results suggest that a major reason for this is the relatively lower MME provided by typical methadone
154 doses compared to typical illicit fentanyl consumption patterns. For instance, typical starting doses of

155 methadone for OUD, ranging from 20 to 40mg daily, are approximately equivalent to 94-188 MME daily.
156 Even a high-end dose of 180mg of methadone daily would be equivalent to 846 MME, representing only
157 a small fraction of the estimated 11,000 MME consumed daily by a typical participant in our sample.
158 Methadone doses in this range are unusual, in part because of concerns about dose-dependent QT
159 prolongation.

160 Although it is generally not necessary or clinically appropriate to fully replace illicit opioid dosing
161 during MOUD initiation, the provision of higher induction and maintenance doses of methadone,
162 equivalent to a larger fraction of MME consumed via illicit fentanyl ingestion, may be warranted among
163 patients using illicit fentanyl. Alternatively, augmenting methadone with other agents, such as slow-
164 release oral morphine, may have similar benefits without the QT prolongation risk[26]. This may also help
165 explain improved outcomes seen by some providers when initiating buprenorphine with higher doses,
166 i.e. 'macrodosing'[27], although the unique pharmacological properties of buprenorphine make a direct
167 MME comparison more difficult. Through a nuanced understanding of their patients' illicit fentanyl
168 consumption patterns, and local drug checking results, physicians prescribing MOUD initiation may be
169 able to better tailor dosing to improve patient comfort and improve retention in treatment.

170 ***Limitations***

171 The illicit fentanyl risk environment in Los Angeles is similar to many other locations on the West
172 Coast—characterized by a later arrival of illicit fentanyl compared to most of the county[2], a delayed
173 albeit large-magnitude increase in overdose deaths after the advent of illicit fentanyls[1,18], a more recent
174 arrival of xylazine as a co-adulterant[14,19], and a predominance of smoking over injection use[20–22].
175 Although the illicit drug market in LA is broadly reflective of trends in the West Coast, the data leveraged
176 here may have certain biases. Information collected from community-based drug checking programs is
177 subject to convenience sampling and may not be representative of the illicit drug supply in Los Angeles
178 as a whole. The purity of fentanyl likely varies by geography. Consumption patterns may be higher

among drug checking participants compared to other people who use opioids, as this likely represents a population with high-volume illicit fentanyl intake. Additionally, we only included fentanyl potency from two fentanyl analogs (fentanyl and fluorofentanyl), which composed the vast majority of our sample, and which were assumed to be equipotent. Literature suggests that this is a generally reasonable assumption[19], however it may have had a small effect on the study results. For simplicity we did not by not include a small number of other fentanyl analogs contained in our samples (e.g. 7 quantified carfentanil samples)[15]. This may have slightly underestimated the true overall potency of illicit fentanyl samples in our study population.

We used literature sources to describe a range of plausible values for bioavailability and MME conversion factors. These factors considerably affect study results and yet limited high quality data are available to guide their selection. Where possible, we used conservative estimates for these parameters, e.g. adding an assumed 27%-45% of drug product left in the pipe or lost to the environment when smoking/vaporizing illicit fentanyl, or an average MME conversion factor of 1:180 between IV fentanyl and PO morphine (whereas 1:300 is the most typical value described in literature). Nevertheless, given the overall extreme magnitude of estimated MME in our results, these assumptions are unlikely to change the main study conclusions.

Further research is needed to better characterize the bioavailability and other pharmacodynamic and pharmacokinetic properties of illicit fentanyl vaporized or smoked via different methods (e.g., pipe, foil, dabber). Additionally, the role of underlying disease processes (e.g., COPD, asthma, pulmonary hypertension) on illicit fentanyl dosing and absorption deserves consideration.

Conclusions

We provide the first effort, to our knowledge, to quantify the MME consumed by people who regularly use illicit fentanyl. We find that the median consumption of nearly 11,000 MME is vastly higher than clinical guidelines or typical methadone doses. This may explain highly elevated overdose mortality rates

203 in the fentanyl era, as well as increased difficulty of MOUD initiation. Further research is needed to
204 assess the degree to which these findings generalize beyond this high acuity population in Los Angeles.

205 **Funding**

206 JRF received funding from the National Institute on Drug Abuse (DA049644) and the National institute of
207 Mental Health (MH101072). AJK received educational support through the NIH/National Center for
208 Advancing Translational Science (NCATS) UCLA CTSI (TL1TR001883). CLS received support from the
209 National Institute on Drug Abuse (K01DA050771). This work was supported by the Centers for Disease
210 Control and Prevention as part of Overdose Data to Action: LOCAL (CDC-RFA-CE-23-0003), and made
211 possible through an equipment grant from the James B. Pendleton Charitable Trust to the UCLA AIDS
212 Institute and UCLA Center for AIDS Research. The funders played no role in the design and conduct of
213 the study; collection, management, analysis, and interpretation of the data; preparation, review, or
214 approval of the manuscript; and decision to submit the manuscript for publication. CLS and JF had full
215 access to all the data in the study and take responsibility for the integrity of the data and the accuracy of
216 the data analysis.

217 **Conflicts of Interest**

218 Authors declare no conflicts of interest.



Figure. Model Parameters: Fentanyl Consumption, Percent Concentration (Purity), and Estimated MME Consumed Among Regular Consumers in LA

For each panel, a vertical dashed line shows the distribution median. Top Left: The distribution of self-reported grams of illicit fentanyl consumed per day among regular consumers participating in drug checking services in Los Angeles. Top Right: Percent concentration (purity) of expected fentanyl samples provided by clients at drug checking services in Los Angeles. Bottom Left: The estimated bioavailability of participants corresponding to their reported routes of administration (e.g. oral ingestion, smoking, snorting, injecting). Bottom Right: the estimated distribution of milligrams of oral morphine equivalent (MME) consumed among drug checking participants in Los Angeles.

References

1. Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010-2021. *Addict Abingdon Engl*. 2023;118(12):2477-2485. doi:10.1111/add.16318
2. Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: Recent evidence from county and state surveillance. *Drug Alcohol Depend*. 2020;216:108314. doi:10.1016/j.drugalcdep.2020.108314
3. Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. *Drug Alcohol Depend*. 2019;204:107547. doi:10.1016/j.drugalcdep.2019.107547
4. Mercadante S, Villari P, Ferrera P, Casuccio A, Fulfaro F. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. *Cancer*. 2002;95(1):203-208. doi:10.1002/cncr.10636
5. Fortnightly Review: Morphine in cancer pain: modes of administration. *BMJ*. 1996;312(7034):823. doi:10.1136/bmj.312.7034.823
6. Starlander J, Melin-Johansson C, Jonsson H, Axelsson B. Oral-Parenteral Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized Crossover Pilot Study. *Pain Res Treat*. 2011;2011:1-5. doi:10.1155/2011/504034
7. Althoff KN, Leifheit KM, Park JN, Chandran A, Sherman SG. Opioid-related overdose mortality in the era of fentanyl: Monitoring a shifting epidemic by person, place, and time. *Drug Alcohol Depend*. 2020;216:108321. doi:10.1016/j.drugalcdep.2020.108321
8. Krotulski AJ, Shinefeld J, DeBord J, Logan BK. *Fentanyl Purity, Potency, & Synthesis: Real-Time Testing of Opioid Drug Products in the United States.* Center for Forensic Science Research and Education; 2022. Accessed March 12, 2025. https://www.drugsandalcohol.ie/36835/
9. Thakrar AP, Kleinman RA. Opioid withdrawal management in the fentanyl era. *Addiction*. 2022;117(9):2560-2561. doi:10.1111/add.15893
10. Shearer D, Young S, Fairbairn N, Brar R. Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series. *Drug Alcohol Rev*. 2022;41(2):444-448. doi:10.1111/dar.13394
11. Ciccarone D. Fentanyl in the US heroin supply: A rapidly changing risk environment. *Int J Drug Policy*. 2017;46:107-111. doi:10.1016/j.drugpo.2017.06.010
12. Delaney SR, Konforte D, Stefan C, et al. Drug checking services as a surveillance tool for clinical laboratories: Examining trends in the unregulated fentanyl supply. *Clin Biochem*. 2023;111:11-16. doi:https://doi.org/10.1016/j.clinbiochem.2022.11.003
13. Shover CL, Godvin ME, Appley M, et al. UV Stabilizer BTMPS in the Illicit Fentanyl Supply in 9 US Locations. *JAMA*. Published online February 5, 2025:e2427550. doi:10.1001/jama.2024.27550
14. Friedman J, Molina CA, Koncsol AJ, et al. Xylazine Prevalence and Concentration in the Los Angeles Fentanyl Market, 2023 – 2025. *Drug Alcohol Depend Rep*. Published online 2025:100364. doi:https://doi.org/10.1016/j.dadr.2025.100364
15. Shover CL, Koncsol AJ, Godvin ME, et al. High variation in purity of consumer-level illicit fentanyl samples in Los Angeles, September 2023–April 2025. *Int J Drug Policy*. 2025;145:104977. doi:10.1016/j.drugpo.2025.104977
16. Sisco E, Verkouteren J, Staymates J, Lawrence J. Rapid detection of fentanyl, fentanyl analogues, and opioids for on-site or laboratory based drug seizure screening using thermal desorption DART-MS and ion mobility spectrometry. *Forensic Chem*. 2017;4:108-115. doi:10.1016/j.forc.2017.04.001

17. Appley MG, Robinson EL, Thomson A, Russell E, Sisco E. An analytical platform for near real-time drug landscape monitoring using paraphernalia residues. *Forensic Chem*. 2023;34:100489. doi:10.1016/j.forc.2023.100489
18. Shover CL, Godvin ME, Appley M, et al. UV Stabilizer BTMPS in the Illicit Fentanyl Supply in 9 US Locations. *JAMA*. Published online February 5, 2025. doi:10.1001/jama.2024.27550
19. Canfield JR, Fry KK, Sprague JE. Enhanced pharmacokinetic and pharmacodynamic effects of combining p-fluorofentanyl and fentanyl. *Drug Alcohol Depend*. 2025;272:112710. doi:https://doi.org/10.1016/j.drugalcdep.2025.112710
20. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645. doi:10.1001/jama.2016.1464
21. Bailey K, Abramovitz D, Artamonova I, et al. Drug checking in the fentanyl era: Utilization and interest among people who inject drugs in San Diego, California. *Int J Drug Policy*. 2023;118:104086. doi:10.1016/j.drugpo.2023.104086
22. Ciccarone D, Ondocsin J, Mars S. Heroin uncertainties: exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin.' *Int J Drug Policy*. 2017;46:146-155. doi:10.1016/j.drugpo.2017.06.004
23. Bolshakova M, Simpson KA, Ganesh SS, Goldshear JL, Page CJ, Bluthenthal RN. The fentanyl made me feel like I needed more methadone": changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl. *Harm Reduct J*. 2024;21(1):156. doi:10.1186/s12954-024-01075-x
24. Santo T Jr, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021;78(9):979-993. doi:10.1001/jamapsychiatry.2021.0976
25. Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021. *JAMA Netw Open*. 2023;6(8):e2327488. doi:10.1001/jamanetworkopen.2023.27488
26. Klimas J, Gorfinkel L, Giacomuzzi SM, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. *BMJ Open*. 2019;9(4):e025799. doi:10.1136/bmjopen-2018-025799
27. Tsui JI, Bhatraju EP, Hallgren KA, Rhew IC, Samet JH. High-Dose Buprenorphine Treatment in the Setting of Fentanyl. *JAMA Netw Open*. 2025;8(8):e2528119-e2528119. doi:10.1001/jamanetworkopen.2025.28119

Supplemental Methods

Purity

1. Data describing fentanyl purity and daily quantity ingested among regular consumers were assessed via data generated from anonymous participants accessing a community-based drug checking program, *Drug Checking Los Angeles*. Participants voluntarily provide samples of illicit drug products for testing at multiple different sites in Los Angeles County, California from September 2023 to July 2025.
2. Samples were analyzed initially in the field with Fourier-transform infrared (FTIR) spectroscopy and immunoassay test strips. Samples were then sent to the National Institute of Standards and Technology (NIST) for secondary laboratory-based qualitative and quantitative testing using direct analysis in real time mass spectrometry (DART-MS) and liquid-chromatography mass spectrometry (LC-MS). Both FTIR and DART-MS assess samples against libraries of over 1,300

substances, including pharmaceutical and illicit drugs, adulterants, cutting and bulking agents, precursor chemicals, and other substances (e.g., adhesives, food products, etc.). The LC-MS quantification panel initially included twelve substances: fentanyl and fluorofentanyl, fentanyl precursor chemicals (4-ANPP, phenethyl 4-ANPP), heroin, methamphetamine, cocaine, α2-agonists (xylazine and medetomidine), and three common fentanyl adulterants (tetracaine, lidocaine, and Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS), and was later broadened to include additional fentanyl analogs and other substances of interest in December 2024. Lidocaine and BTMPS were added to the quantitation panel in July 2024.

3. Of n=1,983 total available samples, this study included n=384 that were sold as fentanyl, expected to contain fentanyl, per client self-report, and had quantified results available based on LC-MS for fentanyl, fluorofentanyl, or both. Only n=3 samples contained fluorofentanyl but not fentanyl.
4. Samples which were designated to be below the LC-MS limit of quantitation were imputed to be 0.1% by mass for purposes of analysis.
5. The 381 available fentanyl purity values were resampled with replacement to create 10,000 draws representing the distribution of purity using the sample() function in R. A seed was set to ensure the reproducibility of results between code iterations.

Drug Quantity Consumed

1. Information on drug quantity consumed for fentanyl (and other drugs) were collected through an anonymous, optional survey conducted by trained drug checking staff.
2. A total of n=31 participants who regularly consume fentanyl self-reported the quantity of fentanyl product they consume in grams and had the option to report the quantity per day, week, or month. Weekly values were converted to days by dividing by 7. Monthly values were converted to daily by dividing by 30. They also self-reported which of the following routes of administration they use to consume fentanyl: inject (IV or IM), smoke, snort, oral, or rectal.
3. The 31 available fentanyl quantity values (alongside associated route of administration information) were resampled to create 10,000 draws representing the distribution of daily fentanyl consumption using the sample() function in R.

Bioavailability and Equivalence

1. Literature values were used to estimate credible intervals for all other model parameters, including bioavailability and MME conversion factors.
2. Bioavailability of orally consumed fentanyl was estimated using the below studies. Each use distinct formulations of fentanyl designed for buccal absorption. They may not be fully comparable to powder fentanyl absorbed via buccal mucosa and the GI tract. Overall, the oral bioavailability was estimated using a normal distribution with a mean of 30%, with a standard deviation of 10%, which is larger variance than the below studies, but accounts for uncertainty due to differences in formulation.
    a. Vasisht, N., Gever, L.N., Tagarro, I., Finn, A.L., n.d. Single-Dose Pharmacokinetics of Fentanyl Buccal Soluble Filmpme_8751017..1023.

386 i. This study estimated oral bioavailability at 35%.
387 b. Darwish, M., Kirby, M., Robertson, P., Tracewell, W., Jiang, J.G., 2007. Absolute and
388 Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate.
389 The Journal of Clinical Pharma 47, 343–350.
390 https://doi.org/10.1177/0091270006297749.
391 i. This study estimated oral bioavailability of a formulation of oral fentanyl at 31%,
392 with a standard error of 3.6%.
393 c. Streisand, J.B., Varvel, J.R., Stanski, D.R., Maire, L.L., Ashburn, M.A., Hague, B.I., Tarver,
394 S.D., Stanley, T.H., 1991. Absorption and Bioavailability of Oral Transmucosal Fentanyl
395 Citrate. Anesthesiology 75.
396 i. The oral bioavailability of fentanyl was estimated at about 33% absorbed
397 through the gastrointestinal tract.
398 3. Bioavailability of vaporized (often referred to colloquially as 'smoked') fentanyl was estimated
399 from the below studies (A and B), which ranged from78%-100% bioavailability when using
400 specialized devices to vaporize fentanyl at a precise temperature and minimize vapor lost to the
401 environment. Therefore, these studies would represent a reasonable upper bound of
402 bioavailability in real-world conditions. It was therefore additionally assumed that 27%-45% of
403 the total drug is left in the pipe/on the foil, or lost to the environment (based on evidence from
404 the methamphetamine literature [C and D below], given a lack of literature describing this
405 phenomenon for illicit fentanyl). The resulting total range of bioavailability of smoked/vaporized
406 fentanyl was 42.9% to 83.0%, represented by a uniform distribution ranging from 42.9% to 83.0%
407 (corresponding to a mean of 62.95%).
408 a. MacLeod, D.B., Habib, A.S., Ikeda, K., Spyker, D.A., Cassella, J.V., Ho, K.Y., Gan, T.J., 2012.
409 Inhaled Fentanyl Aerosol in Healthy Volunteers: Pharmacokinetics and
410 Pharmacodynamics. Anesthesia & Analgesia 115, 1071–1077.
411 https://doi.org/10.1213/ANE.0b013e3182691898
412 i. This study estimated bioavailability of 96.8%, standard error of 7.62%.
413 b. Mather, L. E. , Woodhouse, A. , Ward, M. E. , Farr, S. J. , Rubsamen, R. A. & Eltherington,
414 L. G. (1998). Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis
415 of systemic delivery. *British Journal of Clinical Pharmacology, 46* (1), 37-43.
416 i. Estimated bioavailability as 78%-100% depending on dose, using specialized
417 device to vaporize fentanyl.
418 c. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-
419 administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.
420 Drug Metab Dispos. 1993;21(4):717-723.
421 i. The authors estimated 26.9% of methamphetamine was left in the pipe by users.
422 d. Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The
423 bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther.
424 2003;74(5):475-486. doi:10.1016/j.clpt.2003.08.002.
425 i. In this study, 45% of methamphetamine was estimated to be left in the pipe.

4. The bioavailability of intranasal ("snorted") fentanyl was estimated using the below studies, which had estimates ranging from 55% to 89%. These were represented with a uniform distribution spanning 55% to 89%, with a mean of 72%.
    a. Nardi-Hiebl S, Ndieyira JW, Al Enzi Y, et al. Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers. *Pain Res Manag*. 2021;2021:2887773. doi:10.1155/2021/2887773
        i. Mean estimate 74.70%, standard error of 3.46%.
    b. Foster, D., Upton, R., Christrup, L., Popper, L., 2008. Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery. Ann Pharmacother 42, 1380–1387. https://doi.org/10.1345/aph.1L168
        i. Estimate of 89.0%.
    c. Striebel HW, Kramer J, Luhmann I, Rohierse-Hohler I, Rieger A. Pharmakokinetische Studie zur intranasalen Gabe von Fentanyl. Der Schrnerz 1993;7:122-5.
        i. Range of 55%-71% depending on the pH of the formulation.
5. The bioavailability of injected fentanyl was, by definition, set at 100%.
6. Among the n=31 individuals providing route of administration information alongside quantity of consumption information (resampled to create 10,000 draws) bioavailability was calculated for each draw. If an individual reported multiple routes of administration, then the average of the bioavailability coefficients was used for that draw. In effect, this assumes that individuals evenly split their consumption between the different methods they reported. This could underestimate or overestimate their total absorption depending on their true route of administration habits and the relative frequencies of each method of consumption.
7. Milligrams of morphine equivalence factors between IV fentanyl and IV morphine were obtained from the below literature sources. Equivalence was defined as ranging from 33 to 100.
    a. Ing, M.C., Keane, O.A., Lakshmanan, A., Kim, E., Lee, H.C., Kelley-Quon, L.I., 2024. Opioid equipotency conversions for hospitalized infants: a systematic review. J Perinatol 44, 1709–1718. https://doi.org/10.1038/s41372-024-02121-z.
        i. This systematic review summarized n=8 studies from adult patients (excluding those describing pediatric populations), which had MME conversion factors between IV fentanyl and IV morphine ranging from 33 to 100, with n=6 studies reporting a factor of 100, n=2 reporting a factor of 50 to 100, and n=1 reporting a factor of 33.
8. The equivalence between oral morphine and IV morphine was obtained from the following sources, and was therefore defined as ranging from 2 to 3.
    a. Mercadante, S., Villari, P., Ferrera, P., Casuccio, A., Fulfaro, F., 2002. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 95, 203–208. https://doi.org/10.1002/cncr.10636.
        i. The IV to PO equivalence was defined as ranging from 1:2 to 1:3.
    b. Fortnightly Review: Morphine in cancer pain: modes of administration, 1996. . BMJ 312, 823. https://doi.org/10.1136/bmj.312.7034.823.

467 i. The IV to PO equivalence was defined as 1:3.
468 c. Starlander, J., Melin-Johansson, C., Jonsson, H., Axelsson, B., 2011. Oral-Parenteral
469 Conversion Factor for Morphine in Palliative Cancer Care: A Prospective Randomized
470 Crossover Pilot Study. Pain Research and Treatment 2011, 1–5.
471 https://doi.org/10.1155/2011/504034.
472 i. The IV to PO equivalence was defined as 1:2, with a standard of 1:3 also
473 recognized as reasonable.
474 9. MME factors converting from IV fentanyl to oral morphine were obtained by multiplying the
475 conversion factors in steps 7 and 8 above, yielding a final distribution ranging from 66 to 300.
476 This was represented by a uniform distribution, with a range of 66 to 300, and a median of
477 181.9.

478

479 **Calculations**

480 1. Calculations were performed according to the equation listed in the main text for the 10,000
481 draws of each parameter, derived as defined above. The distribution of quantity consumed,
482 purity, and MME was graphed directly across the draws, and summary statistics (median and
483 range) were calculated for each parameter.